T. Rowe Price Associates
SANA icon

T. Rowe Price Associates’s Sana Biotechnology SANA Stock Holding History

T. Rowe Price Associates’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$988K Buy
282,916
+75,424
+36% +$243K ﹤0.01% 2342
2026
Q1 		$598K Sell
207,492
-558,995
-73% -$2.2M ﹤0.01% 2368
2025
Q4 		$3.12M Buy
766,487
+620,370
+425% +$2.78M ﹤0.01% 1568
2025
Q3 		$519K Sell
146,117
-2,411,708
-94% -$8.72M ﹤0.01% 2339
2025
Q2 		$6.98M Sell
2,557,825
-96,313
-4% -$199K ﹤0.01% 1197
2025
Q1 		$4.46M Sell
2,654,138
-454,479
-15% -$1.27M ﹤0.01% 1284
2024
Q4 		$5.07M Buy
3,108,617
+219,498
+8% +$655K ﹤0.01% 1289
2024
Q3 		$12M Sell
2,889,119
-228,877
-7% -$1.2M ﹤0.01% 1106
2024
Q2 		$17M Sell
3,117,996
-577,463
-16% -$4.6M ﹤0.01% 995
2024
Q1 		$37M Buy
3,695,459
+101,434
+3% +$760K ﹤0.01% 806
2023
Q4 		$14.7M Sell
3,594,025
-3,432,116
-49% -$12.6M ﹤0.01% 1021
2023
Q3 		$27.2M Buy
7,026,141
+1,902,713
+37% +$10.2M ﹤0.01% 844
2023
Q2 		$30.5M Buy
5,123,428
+612,642
+14% +$3.53M ﹤0.01% 831
2023
Q1 		$14.8M Buy
4,510,786
+246,294
+6% +$984K ﹤0.01% 992
2022
Q4 		$16.8M Buy
4,264,492
+623,989
+17% +$3.05M ﹤0.01% 959
2022
Q3 		$21.8M Buy
3,640,503
+748,922
+26% +$5.4M ﹤0.01% 879
2022
Q2 		$18.6M Buy
2,891,581
+841,448
+41% +$5.36M ﹤0.01% 1188
2022
Q1 		$16.9M Buy
2,050,133
+845,437
+70% +$6.84M ﹤0.01% 1273
2021
Q4 		$18.6M Buy
1,204,696
+17,587
+1% +$339K ﹤0.01% 1302
2021
Q3 		$26.7M Sell
1,187,109
-3,090
-0.3% -$64.9K ﹤0.01% 1223
2021
Q2 		$23.4M Sell
1,190,199
-16,511
-1% -$374K ﹤0.01% 1263
2021
Q1 		$40.4M Buy
+1,206,710
New +$39.3M ﹤0.01% 1077

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return

T. Rowe Price Associates's SANA Position: Q2 2026 in Review

T. Rowe Price Associates increased its Sana Biotechnology (SANA) stake by 36% in Q2 2026, buying an estimated $243K and bringing the position to 282,916 shares worth $988K. The position accounts for ﹤0.01% of the portfolio, ranked #2342.

T. Rowe Price Associates first reported a position in SANA in Q1 2021 and has held it in 22 quarters since. The position peaked at $40.4M in Q1 2021. 211 funds tracked by Wall St. Rank hold SANA as of Q2 2026.

  • T. Rowe Price Associates held 282,916 shares of Sana Biotechnology worth $988K as of Q2 2026.
  • T. Rowe Price Associates bought 75,424 Sana Biotechnology shares in Q2 2026, an estimated $243K.
  • Sana Biotechnology made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2342 holding.
  • T. Rowe Price Associates first reported a position in Sana Biotechnology in Q1 2021 and has held it in 22 quarters since.
  • T. Rowe Price Associates's Sana Biotechnology position peaked at $40.4M in Q1 2021.
  • 211 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.